Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a combination containing **two doses of budesonide** and **one dose of formoterol**. Budesonide is a synthetic corticosteroid that reduces lung inflammation, while formoterol is a long-acting β2-adrenergic agonist (LABA) that relaxes airway smooth muscle, leading to bronchodilation. These drugs are commonly used together to treat asthma and chronic obstructive pulmonary disease (COPD) via inhalation. However, the specific combination of "budesonide + budesonide + formoterol" (i.e., two discrete doses of budesonide plus one formoterol in a single inhaler or product) does not correspond to any widely recognized or marketed formulation; standard products contain a single dose of budesonide combined with formoterol, as in the fixed-dose combination found in products like Symbicort[1][2][3][4][5][6]. Therefore, this is either a misstatement or an uncommon formulation. Both components target different mechanisms to control airway inflammation and bronchospasm: budesonide acts as an anti-inflammatory agent, and formoterol as a bronchodilator.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + budesonide + formoterol.